Catholic University Industry Academic Cooperation Foundation

Lg Chem, Ltd

The Catholic University of Korea Industry-academic Cooperation

Mitoimmune Therapeutics Inc.

Jung Yeon Lim

Dong-Woo Cho

Sun Hwa Park

Seok Goo Cho

Sung Won Kim

Byeong Gon Yoon

Jinah Jang

Sun Woo Park

Eun Jung Kim

Nayoun Kim

Seung Ki Kwok

Keon-Il Im

Jaeseon Lee

Eun Sol Lee

Eun Joo Jeon

Young Sun Nam

Na Youn Kim

Keon Il Im

Provided are a method for fabricating a human nasal turbinate-derived mesenchymal stem cell-based 3D bioprinted construct, and a use thereof, wherein the human nasal turbinate-derived mesenchymal stem cell-based, 3D bioprinted construct is advantageous over conventional mesenchymal stem cell-based, 3D bioprinted constructs in that the former can survive and proliferate stably in vitro and/or in vivo and shows high osteogenic differentiation ability as well, therefore is expected to make a great contribution to the practical use of cellular therapeutic agents.

Human nasal turbinate-derived mesenchymal stem cell-based, 3D bioprinted construct, and use thereof

The present invention relates to a pharmaceutical composition for preventing or treating rheumatoid arthritis, and a stem cell therapeutic agent for treating rheumatoid arthritis, comprising nasal inferior turbinate-derived mesenchymal stem cells as an active ingredient. Nasal inferior turbinate-derived mesenchymal stem cells of the present invention have the effects of reducing the production of interleukin-17A (IL-17A), tumor necrosis factor-&#x3b1; (TNF-&#x3b1;), immunoglobulin G2 (IgG2a) which is an inflammation-inducing factor, and/or the proliferative ability of lymph node T cells, increasing interleukin-10 (IL-10) and/or regulatory T-cells (Treg, CD4CD25foxp3cell) that contribute to immune tolerance in spleen cells, and inhibiting the proliferation of human T-cells. The nasal inferior turbinate-derived mesenchymal stem cells have a safer acquisition process than existing mesenchymal stem cells and can be acquired in sufficient amounts within a desired period of time, thus allowing mesenchymal stem cells to be acquired at low cost and high efficiency. Moreover, since the nasal inferior turbinate-derived mesenchymal stem cells have the same genetic origin as individuals administered therewith there are few side effects, the nasal inferior turbinate-derived mesenchymal stem cells can be usefully used for preventing or treating in individually tailored immunocompatible rheumatoid arthritis.

Pharmaceutical composition for preventing or treating rheumatoid arthritis comprising nasal inferior turbinate-derived mesenchymal stem cells as an active ingredient

The present invention relates to a composition for preventing or treating mucositis comprising NecroX. It was found that NecroX has effects of reducing the disease mortality rate by means of radiotherapy or chemotherapy in a NecroX administration group, protecting intestinal functions, inhibiting destruction of intestinal mucous membrane, and proliferating the cells present in intestines. NecroX may be used for a pharmaceutical composition for preventing or treating mucositis, an anti-cancer adjuvant, or a food composition.

Composition for preventing or treating mucositis comprising NecroX as effective ingredient

The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and/or for inducing differentiation into regulator T cells from undifferentiated T cells and/or promoting proliferation of regulator T cells.

Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator T cells and promoting proliferation of regulator T cells

Growing community of inventors

Seoul, South Korea

Jung Yeon Lim